Introduction
Today stroke is in the top 10 causes of death in the world. It maintains the position as the leading killer, and accounts for more than 6 million deaths annually [1] . In Ukraine, it is near 100 000 cases each year, and almost 40 000 of them are fatal [2] .
Risk of stroke is rising in direct proportion to the patient's age. However, it is observed its rising incidence among young people up to 40 years old in age [2, 3] . Stroke affects men and women equally and causes major social and economic burdens to society: 80 % of survivors are disabled until the end of life [4] . This is the third most common cause of disability-adjusted life-years worldwide [4, 5] . More than 80 % of all strokes are ischemic and characterized by occlusion of brain vessel of thrombi or embolus.
the aim of the study is to find the effective cerebroprotector among original synthesized coordination compounds of germanium in the experimental model of acute global cerebral ischemia.
Methods experiments were performed on white inbred rats, males and females, 180-220 g of body weight. Acute brain ischemia was modeled by bilateral occlusion of both common carotid arteries before its bifurcation to external and internal branches under thiopental general anesthesia.
All animals' procedures were carried out according to the rules and requirements of European Convention for the Protection of Vertebrate animals used for experimental and other Scientific Purposes as well as eu directives 2010/63/EU.
For primary screening we used numerous bis(citrate)germanates (stannates) compounds, which contained different metals: magnesium bis(citrate) germanate (germacit), mangan bis(citrate) germanate (Ol1), cobalt bis(citrate) germanate (Ol2), nickel bis(citrate) germanate (Ol3), zinc bis(citrate) germanate (Ol4), mag-V. D. Lukianchuk et al. all used germanium complexes were administered to rats at the doses according to the results of our previous studies [6, 7] . We injected them intraperitoneally in the form of 1 % aqueous solution at a dose of 50 and 100 mg/kg in 35 min after bilateral common carotid artery occlusion.
As a comparator (reference) drug, Piracetam medication was used (Farmak, Ukraine, 20 % solution in 5 ml ampules). It was injected intraperitoneally at a dose of 350 mg/kg in 30 min after ischemia. The rats of control group (ischemia without any correction) got equivalent dose of saline.
Criteria of cerebroprotector activity of the studied compounds were: survival of rats (%) each hour during the first 12 hours, then on the 24 th , 48 th and 72 nd hours of ischemia; monitoring the clinical signs for ET 50 (median effective timethe time required for a half as organisms in a toxicity test to reveal the nonlethal response). It was evaluated to be ET 50 =f(N/2) by interpolation of data of lethality time to mathematical function T=f(N), where T is the time of animals death, N -the number of animals. Neurological status was assessed by Irwin's test in the model of acute brain ischemia and administration of germanium compounds. The primary observation test was used for rodents to assess acute toxicity of a test agent and its effects on behavior and physiological function [8, 9] .
Statistical analysis. Statistical analysis of animals' survival have been carried out using the nonparametric criterion fisher's exact test and average time of lifespan by use of t-criterion of Students' test. All data were presented as M (mean) ± m (standard error). A probability level (p value) of less than 0.05 was considered to be statistically significant.
Results
The results obtained in the screening model of global brain ischemia are presented in the Table 1 . Almost all bis(citrate) germanates (stannates), which contained different metals, possessed anti-ischemic activity of different intensity. the exception was the ol-6 compound, which comprised cobalt. Even at the dose of 50 mg per kg in this group during the first hour of occlusion of aa. carotica communes the rate of rats survival was only 28.5 % opposite to 100 % in the control group. In addition, the other cobalt-containing compound Ol-2 proved very low efficacy for cerebroprotection.
As for the results in Table 1 , the most significant efficacy on the 48 th hour of the experiment was evidenced for VitageRM-1 -a coordination compound of germanium, diethylenetriaminepentaacetic acid and lithium. The animals' survival in this group was 57.1 % compared to 100 % lethality in the control group. It is important that the anti-ischemic activity of VitageRM-1 exceeded even the effect of reference drug Piracetam.
To estimate the obtained screening results more profoundly and detail, we suggested and used in our experiment the index of median effective time ET 50 . According to the results presented in Table 1 , ET 50 for group of rats administered with vITAGERM-1 was 53.31±2.77. It was in 7.5, 3.0 times better compared to the control and reference group respectively.
At the same time to make an all-round comparison analysis of the results of screening series we assessed clinical signs of acute ischemia: neurological status of rats, which got the different types of germanium compounds. All data are presented in Table 2 .
The rats with stroke, on the model we chose, experienced the severe clinical signs of global ischemia. The animals of control group after occlusion of both carotid arteries became less alert and more passive. It was proved by the indices of emotional condition: grooming decreased up to 0 points, vocalization increased up to 1.4. The tonus of limbs also diminished, ataxia signs increased up to 2.9 points. the character of these neurological changes testified quite a deep injury of brain cortex because of global ischemia. It resulted in the disruption of motor activity in the control group rats: suppression of reactions to touch and knock up to 1.5 and 1.9 points respectively. Brain ischemia also strengthened the tremor up to 2.3 points. The suppression of ptosis reaction in 2.1 times as well as increased 1 and 2.2) . the significant increase of alertness up to 3.0 points and decreasing of expressiveness of passivity by 41.0 % was fixed in this group compared to the control rats. This investigated compound increased the grooming and normalized the vocalization. Administration of VitageRM-1 led to absence of ataxia and increase of extremities tonus up to 3.3 points that was nearly the same as the indices of the intact rats. Responses to touch and knock intensified also up to 3.6 and 3.5 points respectively in comparison to the control.
We noticed total positive effects of this germanium compounds in prevention of tremor, urination and defecation; the ptosis rate increased up to 2.2 points.
Discussion the pathophysiology of stroke is complex, and involves inflammatory pathways, oxidative damage, apoptosis, energy deficiency etc. the main goal of treatment is to preserve tissues in ischemic penumbra, where perfusion is decreased but sufficient to stave off infarction, and save the neurons (neuroprotection) [4, 5] .
Ischemic stroke and its consequences is a major public health problem. In spite of huge number of medications to treat it, we still have no perfect one according to the present requirements of safety and efficacy. that is why the search and investigation of newly synthesized organic and other compounds with capability for stroke protection is an actual challenge and target for chemists, pharmacologists, physicians and health professionals.
Numerous bis(citrate) germanates (stannates) compounds with wide spectrum of therapeutic activity are synthesized and investigated today. our previous experiments proved its low toxicity to warm-blooded species [10, 11, 12] . Use of the rodent models is recommended and approved by different researches for screening and investigating of promising compounds to prevent and treat ischemic brain lesions [13] . In the screening series in the model of global brain ischemia (via occlusion of both common carotid arteries before its bifurcation), it was determined that almost all compounds had potency for stroke protection. Such criteria as survival and median effective time plus Irwin's test results were adequate to evaluate it [14, 15] . Piracetam was used as a reference drug [16] .
Among all investigated bis(citrate) germanate (stannates) compounds, which contained different metals, the most potent anti-ischemic activity was possessed by coordination compound of germanium, diethylenetriaminepentaacetic acid and lithium coded as vITAGERM-1. It was a leader among the germanium compounds according to the analyses of the indices of survival and lifespan of rats from the moment of occlusion of coronary arteries.
Such positive effects were manifested by the highest level of survival and the most favorable clinical course of cerebrovascular blood circulation. Median effective time ET 50 in this group exceeded in 7.5 and 3.0 times the index of control and reference group respectively. We noticed total positive effects of this germanium compounds in prevention of disorders of behavioral, neurological and autonomic profiles of rats. Therefore, we concluded the prominent improvement of clinical course of acute brain ischemia under the vitagerm-1 impact.
We suppose that the presence of the cobalt in structure of Ol-2 and Ol-5 molecules is responsible for animals lethality during the first hour after the disorder development. low efficacy of these germanium compounds could be explained by the fact that this metal is a cytochrome P450 inhibitor. The cytochromes P450 (CyPs) enzyme family are crucial in processes of detoxification of the organism, and suppression of its activity is one of the most possible causes of high lethality in cases of experimental global brain ischemia [17] .
Conclusions
Almost all bis(citrate) germanates (stannates), which contained different metals, possessed anti-ischemic activity of different intensity. the exceptions were cobalt-containing ol-6 and ol-2 compounds. the most expressive efficacy for all investigated indices (which exceeded even the reference drug) proved for vITAGERM-1 -a coordination compound of germanium, diethylenetriaminepentaacetic acid and lithium.
the results of our experiments are suggested for the substitution for further deeper pharmacological investigation of vITAGERM-1 for stroke cerebroprotection, and its implementation into clinical practice.
